Directory · NO
Biotechnology in Norway
A register of firms and the professionals working at them in the Biotechnology sector based in Norway. Browse the public index, then filter or export on Kipplo.
Companies
34 on file
Geno Sa
With 90 years of innovation and genetic improvement of the Norwegian Red, the genetic organization Geno is at the forefront of genetic progress in dairy cattle. Geno analyzes more than 50 DNA markers within the Norwegian Red breed for traits like fertility, disease resistance, and production as part of the HD Genomics breeding program, which includes one of the most extenisve records of phenotypes in the world. The result is healthy genetics with world-leading fertility, superior functional traits and excellent production. This provides farmers with unique, reliable genetics for efficient and economical operations – now and in the future. At Geno SA, our mission is to breed for better lives, for dairy farmers and dairy cattle. Our mission is grounded in our 9 owners and dairy farmers breeding Norwegian Red, and is the result of consistent breeding planning since 1935. We do business in more than 30 countries, and have 230 employees that work closely with our customers to give them the best possible genetics and a sustainable production of protein to feed the world. Our R&D team works closely with world-leading researchers and resources on genomic selection and other genetic technologies. With vast amounts of information, the Norwegian Red breed has been the subject of many research projects resulting in numerous doctorate degrees. This is what builds the base for the success of the Norwegian Red. Probably the most efficient breed in the world. Geno Group: Geno SA Geno Global Ltd. SpermVital Geno SA also owns 52 % of Cryogentics Ltd.(fish milt, etc.)
201 to 500 staff
Nec Oncoimmunity As
NEC OncoImmunity AS is an artificial intelligence (AI) driven biotech company offering proprietary machine-learning software, which addresses the key gaps in the prediction of bona fide immunogenic antigens for personalized cancer immunotherapy and infectious disease vaccines. We are dedicated to developing scalable software solutions that facilitate effective patient selection for cancer immunotherapy, and identifying optimal neoantigen targets for truly personalized cancer vaccines & cell therapies in a clinically actionable time frame. Our growing international team (13 countries and counting!) consists of a diverse mix of data scientists, bioinformaticians, immunologists, cancer researchers, and software developers. NEC OncoImmunity AS is a subsidiary of the NEC Corporation, and is based in the Oslo Cancer Cluster buildings in Oslo, Norway.
11 to 50 staff
Pci Biotech Holding Asa
PCI Biotech is a biopharmaceutical company focusing on developing and commercialising new technologies and novel therapies through its photochemical technology platform originating from world-leading research at the Oslo University Hospital. We are a small team, located at Oslo Cancer Cluster Innovation Park in Oslo, Norway. The company is listed on the Oslo Stock Exchange under the ticker PCIB. The technology platform is under development in two different areas.(1) Photochemical lysis (PCL), for increasing yield and reducing impurities in gene therapy (viral vector) manufacturing.(2) Photochemical internalisation (PCI), inducing light-triggered endosomal release, which may unlock the potential of a wide array of modalities. For further information, please visit: Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo
1 to 10 staff
Lytix Biopharma
Lytix Biopharma is a clinical-stage immunotherpy company developing a new class of oncolytic molecules designed to destroy tumors locally and elicit durable anti-tumor immunity. Our peptide-based oncolytic molecules, derived from host defense peptides, work through a dual mechanism: first, inducing rapid immunogenic tumor cell death that releases tumor antigens into the microenvironment; second, activating a lasting immune response that can prevent recurrence and improve responses to checkpoint inhibitors. Lytix is advancing ruxotemitide as a first-in-class oncolytic peptide for neoadjuvant melanoma, with broad potential across superficial tumors such as basal cell carcinoma and Merkel cell carcinoma. Our partner, Verrica Pharmaceuticals, has reported positive Phase 2 data in basal cell carcinoma, representing industrial validation of the platform. Our pipeline also includes LTX 401, targeting deep-seated tumors with strong preclinical data in liver cancer models. Lytix is positioned to deliver a new generation of immunotherapies that: • Are active against drug resistant cancer cells • Are efficacious, independent of tumor mutational burden and tumor heterogeneity • Elicit a broad T-cell response and infiltration into the tumor microenvironment • Work in synergy with immune checkpoint inhibitors through • Extend benefit to patients who have not responded to previous lines of immunotherapy • Are safely combinable with immune checkpoint inhibitors Headquartered in Oslo, Norway, Lytix Biopharma brings together a world-class advisory network, including Nobel Laureate Jim Allison, and global partners to accelerate the translation of our science into therapies that change the course of cancer treatment. We are building partnerships with pharmaceutical and biotech companies seeking to enhance immune response, improve clinical outcomes, and explore new frontiers in combination oncology.
11 to 50 staff
Rimfrost As
RIMFROST AS has its origins from Norway. The organization has grown to be a leading player in the nutritional sector with a strong focus on the development of innovative krill-derived omega-3 products for human, feed and animal health. The incredible strength of krill comes from its high concentrations of efficient omega-3 fatty acids bound in phospholipids, high quality marine proteins and the powerful antioxidant astaxanthin. RIMFROST AS supports tight regulations and control to ensure the preservation of the Antarctic ecosystem. We are committed to providing high quality krill products through gentle processing and low environmental impact. RIMFROST offers traceability at every step. Having 100% ownership of the short value chain ensures precise quality and reliable production capacity. RIMFROST AS has been certified by Marine Stewardship Council (MSC) and Friend of the Sea.
11 to 50 staff
Sharelab
Premier Scandinavian lab incubator for ambitious bioentrepreneurs. Based at Oslo Science Park. Our goal is simple: to build the next generation of Scandinavian biotech startups.
1 to 10 staff
Blue Analytics
Blue Analytics is an innovative biotechnology company that provides analytical services as a foundation for addressing biological challenges and improvements in the aquaculture and agriculture industries. Our analyses offer insights into the health and characteristics of animals, enabling farmers to make evidence-based decisions for the benefit of welfare and sustainable production. We specialize in the development and execution of diagnostics, disease tracking, and genotyping of fish and other species. These analyses find applications in health monitoring, food safety, breeding programs, and origin determination. The company has a high level of expertise in bacteriology, virology and molecular biology and has been built up in close collaboration with fish health and aquaculture companies since 2010. Blue Analytics is part of EW GROUP, an international holding company headquartered in Germany. EW GROUP consists of approx. 165 companies in 45 countries focusing on four business areas within agriculture and aquaculture; breeding, veterinary medicines, nutrition/feed supplements and diagnostics.
11 to 50 staff
Ah Diagnostics
We provide reagents, instruments and bio appliance for molecular biological and immunological research and diagnostics. Professional sparring and guidance is the core of our work due to our high technology products which are long term investments. With products from more than 35 suppliers, we cover the complete workflow of our customers who work within health care, pharma, biotech and universities. We have more than 30 years of experience serving the Nordic Region and offices located in Aarhus, Copenhagen, Oslo, Stockholm and Helsinki. We are currently 50 employees of which 26 are based in our headquarters in Aarhus.
11 to 50 staff
Age Labs As
Aging is the main cause behind most illnesses that eventually kill us. Your chance of dying doubles every 8 years. By the time you turn 80, half of your peers are dead. However, it turns out aging is a biological process, amenable to treatment. Research has demonstrated that we can postpone the onset of age-related disease. Lab mice know this already. Experiments with caloric restriction, senolytics and metabolic inhibitors have extended life and reversed aging - in mice. But how do we know these treatments will work in humans? We can wait and see if patients receiving these new treatments die later. Or see if onset of age-related disease is postponed. But this is slow. It takes many, many years to know for sure if the treatments work. Wouldn’t it be great if we had a faster way? Thanks to the discovery of the epigenetic clock, we can now accurately describe changes to gene regulation caused by aging. By turning this discovery into a blood test, we can measure the exact aging status inside human cells. This will be incredibly useful to researchers involved in aging research. They would know if a treatment works, much earlier than before. So that’s what we’re making: A biomarker for aging which is accurate, affordable and quick.
1 to 10 staff
The Life Science Cluster
The Life Science Cluster is Norway's largest life science cluster, and a network for all companies and organizations for which the life sciences are key. This includes health and medicine where Norway’s advanced healthcare system forms a unique basis for the development of new technology. It also encompasses the marine sector, agriculture and forestry, where Norway has world leading industries based on our vast natural resources and strong research-based technology development. Our members believe in cooperation and the competitive strengths of being part of a cluster. The Life Science Cluster welcomes as members all companies and organizations, Norwegian and international, with interests in the life sciences. Students and researchers can apply for personal membership.
1 to 10 staff
Ultimovacs Asa
Ultimovacs is a biotech company developing novel immunotherapies against cancer. The lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the nearly universal cancer antigen telomerase, investigated in five randomized Phase 2 trials. UV1 is being developed as a therapeutic cancer vaccine for use in combination with other immuno-oncology drugs, which require an ongoing T cell response for their mode of action. Ultimovacs is performing a broad clinical development program with clinical trials in Europe, Australia, and the USA; Five Phase II trials enrolling more than 670 patients at 100 clinics in 15 countries in melanoma, mesothelioma, head & neck cancer, ovarian cancer, and non-small cell lung cancer. Ultimovacs was established in 2011. The company and its proprietary technology is based on pre-clinical and clinical research on immunotherapies conducted at the Oslo University Hospital. The company is publicly listed at Euronext Oslo (ULTI). Ultimovacs is headquartered at the Oslo Cancer Cluster Innovation Park in Oslo, Norway, and has an office in Uppsala, Sweden.
11 to 50 staff
Syngens
Biology operates like a nano-scale processor, adept at converting sugars, waste, and captured carbon into pharmaceuticals, nutrients, proteins, enzymes, and various chemicals. Current methods for programming biological systems rely heavily on trial and error due to a lack of accurate models, leading to unpredictable results. Utilizing the combined power of artificial intelligence and 'omics data, we bring predictability to biological processes. This approach speeds up the development of new products at reduced costs, greatly boosting our ability to address climate change and move towards a sustainable future.
1 to 10 staff
Bluecirc
Bluecirc er et offensivt utviklingsselskap i sterk vekst, som leverer miljøteknologi til fiskeri- og havbruksnæringen. Selskapet har en bred portefølje av grunnprodukter, og har under utvikling et nytt system for håndtering av biologisk avfall. Systemet behandler biologisk avfall som fiskeavskjær, oppdrettsfisk, slam og annet – og gjør det om til utnyttbare ressurser. Etter lansering kommer dette systemet til å bli vår viktigste driver for videre vekst. Bluecirc har store ambisjoner om å endre næringen i mer bærekraftig retning, og gjøre det enkelt for næringsaktørene å velge mer miljøvennlige løsninger. Det skal være lønnsomt både for dem og for oss. Selskapet ble startet i 2015, har hovedkontor i Kristiansund og drives av langsiktige profesjonelle eiere.
1 to 10 staff
Colifast
Colifast AS is a Norwegian company which is specializing in research, development and production of rapid methods and instrumentation for microbial analysis. The Colifast technology is patented and based on growth media for rapid and specific detection of different indicator bacteria in water and food. In addition, the company has developed several instrument platforms for automated analysis. This provides fully automated On-Line water analysis which is used by many customers for at-site monitoring of raw water, rivers and environmental water, waste water and drinking water. Colifast also provide basic test kits for manual quality control of water and food products. All products are easy to use and designed for testing without laboratory facilities. The technology is tested and verified in several independent international studies and Colifast has established a good reputation based on high quality products and numerous user references. Colifast primarily sell products to municipalities, waterworks, educational institutions and food and beverage industri.
1 to 10 staff
Oxy Solutions As
Oxy Solutions is a privately held Norwegian based biotech company that has developed and patented an innovative technology for highly oxygenating liquid. Oxy Solutions' core business and strategy is to develop, document, IP protect, and commercialize the technology. The company has an in-house R&D facility in Norway. The company has funding from the Norwegian Research Council. Oxy Solutions is in possession of patented technology that makes it possible to greatly increase the dissolved level of oxygen in water. Tests have indicated stable levels in excess of 70 mg/l, or approximately 10 times higher than previously thought possible.
1 to 10 staff
Caedo Oncology As
Our vision is to be a leader in cancer immunotherapy improving patient treatment through novel monoclonal antibodies, inducing programmed cell death in cancer cells. Cancer treatment has generally been based on treatment with drugs and modalities that are cytotoxic to both cancer and healthy cells. Advances in immunotherapy open new possibilities for selective targeting of cancer cells. Caedo Oncology develops new strategies for monoclonal antibody-based therapy centered around activation of distinctive pathways for cell death in cancer cells. The company was established in November 2020 based on research performed at Oslo University Hospital.
1 to 10 staff
Marealis Innovation As
Marealis Innovation AS will develop marine by-products into new products of higher value. With the experience of developing bioactive peptides from Arctic shrimp shell, into a documented and governmentally approved dietary supplement/natural health product with a blood pressure lowering effect comparable to antihypertensive drugs, Marealis Innovation will use this know-how to develop new products from by-products marine origin. Norway has abundant resources of marine by-products of high value. This is valuable protein, fat, minerals, carbohydrates, vitamins, and other molecules which needs to be taken care of for human ingredients or fish/animal feed. Marealis Innovation cares for the rest, and for the future.
1 to 10 staff
Norgenotech As
NorGenoTech is a biomedical technology company providing efficient analysis of DNA damage. We develop equipment, carry out research projects and offer services and training courses.
1 to 10 staff
Thelper
Thelper develops First-in-Class immunotherapy for treating the most aggressive cancers.
1 to 10 staff
Antigrade As
Want to know how we keep food fresher longer? We have partnerships with two of the leading food producers in Norway. Antigrade is a fully natural, non toxic proprietary technology that significantly improves microbial quality, food safety and shelf life of any kind of food and drink, while maintaining taste, nutrition, color and other beneficial factors. Applicable as a product in many forms throughout the value chain, f.ex. in tanks on fishing boats, incorporated in (isopor) boxes for fish export or as an absorber/pad in sealed portion packs. Antigrade is in all respects natural and non-toxic. No chemicals, gas or synthetic influencers in use. Not active or a source of radiation. Antigrade will add value to the entire value chain – from fisheries/farmers to consumers Antigrade can be used throughout the entire value chain for maximum effect: Fisheries/farmers – will be able to use Antigrade to delay bacteria growth immediately from time of harvesting and slaughter, and possibly from earlier while the fish is still alive (the latter to be further confirmed). Fish refineries – will be able to adopt Antigrade while using existing production lines with limited or no investment, allowing them to offer fish of high microbial quality, as well as being able to offer their products to a broader geographical market. In addition the need for workers doing overtime is reduced, a longer shelf life may support a more cost effective choice of transport (ships instead of flights). Food chains/restaurants – will enjoy increased food shelf life and thus reduce food waste, enjoying higher profit margins – which is expected to be a key driver for the Antigrade business. 🤝 Consumers – will benefit from increased microbial quality, food safety and reduced food waste.
1 to 10 staff
Arxx Therapeutics
Founded in 2018, Arxx Therapeutics develops a first-in-class monoclonal antibody with a unique mechanism of action targeting non-resolving tissue fibrosis
11 to 50 staff
Lybe Scientific As
High quality nanoparticle-based solutions for life science, diagnostic and aquaculture purposes: We develop and manufacture products within nucleic acid extraction and sample preparation. We serve customers from hospitals, aquaculture and fish health monitoring as well as academic institutions. Our products simplifies and shorten the sample preparation time with up to 50%!
1 to 10 staff
Inspiring By Euronlabs
Norway's first innovative smart-ring! Get Inspired! Gain personal health insights with a smart & elegant smart-ring. Increase your self-awareness by tracking your own sleep, activity, heart rate, blood oxygen and much more.
1 to 10 staff
Bionor Holding As
Bionor's mission is to enable the immune system to fight HIV infection. Bionor is the first company, which has successfully completed a clinical trial using the shock and kill approach, thereby creating a strong foundation for further advancing its therapeutic vaccine Vacc-4x and Vacc-C5 in combination with other agents towards a functional cure. The company believes it has first mover potential based on clinical results to date and early adoption of the shock and kill strategy. In December 2015, Bionor announced that the HIV trial REDUC with Vacc-4x and romidepsin successfully met its primary endpoint by reducing latent HIV reservoir and further demonstrated control of viral load. Bionor retains full ownership rights to the HIV immunotherapy Vacc-4x and Vacc-C5, i.e, the upside potential from partnering or licensing remains with the Company.
1 to 10 staff
